胃癌多药耐药机制及研究进展  

Research Advances in the Mechanisms of Gastric Cancer Multidrug Resistance

作　　者：黄昊[1] 杨星九 高苒[1] 

机构地区：[1]中国医学科学院医学实验动物研究所北京协和医学院比较医学中心,北京100021

出　　处：《中国医学科学院学报》2016年第6期739-745,共7页Acta Academiae Medicinae Sinicae

基　　金：中央级公益性科研院所基本科研业务费(2016ZX310032);协和青年科研基金(3332016078)~~

摘　　要：胃癌在我国乃至全球范围内仍然是最常见的恶性肿瘤之一,其每年的死亡人数在各类癌症中排名第3。化疗仍是晚期胃癌的主要治疗方案之一,由于不敏感和多药耐药的发展,胃癌的化疗疗效一直较差。虽然近年发现许多新的分子及机制与胃癌多药耐药的发展相关,但对其如何发生多药耐药的详细机制仍不清楚。本文主要综述胃癌多药耐药相关分子的鉴定及多药耐药机制,以便更加深入了解胃癌多药耐药的发生机制,可能为克服胃癌多药耐药提供新的思路。Gastric cancer is one of the most common human malignancies and the third cause of death from cancer in China and worldwide. Chemotherapy is still one of the major treatment options for advanced gastric cancer. However,the efficacy of chemotherapy for gastric cancer remains poor due to its insensitivity and the development of multidrug resistance（ MDR）. While many molecules and mechanisms have been found to be associated with the development of gastric cancer MDR,the specific mechanisms remains unclear. In our current article,we reviews the identification of MDR-related molecules and mechanisms,with an attempt to a better understand the specific mechanisms of gastric cancer MDR and thus provide new insights into the fight against gastric cancer MDR.

关 键 词：胃癌 化疗 多药耐药 

分 类 号：R735.2[医药卫生—肿瘤]